Tempus Ai
2 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 holds ✗
Personalized mRNA cancer vaccines are gaining momentum following Phase III success in melanoma and expanded global clinical trials.
9 sources
9 articles
v 7
42d ago
◼ Archived
Business
🔮 fades
Tempus AI is acquiring cancer-monitoring firm Personalis in a deal valued at approximately $1.5 billion, though market reaction has been negative.
7 sources
7 articles
v 5
90d ago
\n
\n
\n